# US 12,180,247 B2 · Oxysterols and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,247 B2
- Document ID: US12180247B2
- Status: Granted
- Kind: B2
- Application number: 18/106,073
- Filed: 2023-02-06
- Published: 2023-10-19
- Granted: 2024-12-31
- Earliest claimed: 2016-10-18
- Assignees: Sage Therapeutics, Inc.
- Applicants: Sage Therapeutics, Inc.
- Inventors: Francesco G. Salituro; Albert Jean Robichaud; Gabriel Martinez Botella; Boyd L. Harrison; Andrew Griffin
- Web page: https://patentgrep.com/patent/US12180247B2

## CPC

- C07J 43/003: {not condensed}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07J 9/00: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J 9/005: {containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton}
- C07J 17/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton (cardanolide, bufanolide C07J19/00)
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

## Claims

### Claim 1

A compound selected from the group consisting of:

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 5

A pharmaceutically acceptable salt of a compound selected from the group consisting of:

### Claim 6 (depends on 5)

The pharmaceutically acceptable salt of claim 5, wherein the compound is selected from the group consisting of:

### Claim 7 (depends on 5)

The pharmaceutically acceptable salt of claim 5, wherein the compound is selected from the group consisting of:

### Claim 8 (depends on 3)

A pharmaceutical composition comprising a compound of claim 3, and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 4)

A pharmaceutical composition comprising a compound of claim 4, and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 5)

A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 5, and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 6)

A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 6, and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 7)

A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 7, and a pharmaceutically acceptable carrier.